Side-by-side · Research reference

ARA 290vsDSIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED17/59 cited

BHuman-MechanisticAUTO-DRAFTED8/36 cited

ARA 290

EPO-Derived Peptide · Innate Repair Receptor Agonist

4 mgDaily doseBrines 2015 Culver 2017

28 daysPhase 2 durationCulver 2017

Non-erythropoieticSafety profileBrines 2015 Liu 2014

SQ · DailyBrines 2015 Culver 2017

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

01Mechanism of Action

Parameter

ARA 290

DSIP

Primary target

Innate repair receptor (EPO receptor / CD131 heterodimer)

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pathway

EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Downstream effect

Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014 Culver 2017

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Feedback intact?

N/A — does not interact with hematopoietic EPO receptorLiu 2014

—

Origin

11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Antibody development

Not reported in clinical trials

—

02Dosage Protocols

Parameter

ARA 290

DSIP

Standard dose (Phase 2)

4 mg / dayBrines 2015 Culver 2017

Sarcoidosis SFN and diabetic neuropathy trials.

—

Frequency

Once daily

Self-administered subcutaneously.

Once daily, pre-sleep

Duration

28 days (Phase 2)Culver 2017

Corneal nerve improvements observed by day 28.

8–12 weeks per cycle

Evidence basis

Phase 2 RCTsCulver 2017 Brines 2015

64-subject sarcoidosis trial, type 2 diabetes trial.

Human-mechanistic + early clinicalSchneider 1986

Route

SubcutaneousBrines 2015

—

Timing

Any time of day

No circadian dependence reported.

30–60 min pre-sleep

Standard dose

—

100–200 mcg SQ pre-sleepSchneider 1986

Lower / starter dose

—

50 mcg pre-sleep

Reconstitution

—

Bacteriostatic water

Half-life

—

Short plasma; CNS effects last hours

03Metabolic / Fat Loss Evidence

Parameter

ARA 290

DSIP

Primary effect

Improved metabolic control (HbA1c, fasting glucose)Brines 2015

Secondary to neuropathy treatment; direct lipolytic effects not established.

—

HbA1c

Significant reduction vs placebo

Observed in type 2 diabetes + neuropathy trial.

—

Fasting glucose

Improved in ARA 290 group

—

Body composition

Not directly quantified

Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.

—

04Side Effects & Safety

Parameter

ARA 290

DSIP

Injection site reaction

Mild, transient

Mild irritation

Hematopoiesis

None — non-erythropoietic

Distinguishes ARA 290 from native EPO.

—

Cardiovascular

No thrombotic events or hypertension reported

—

Immunogenicity

No antibody formation reported

—

Tolerability

Well-tolerated in Phase 2 trialsCulver 2017 Brines 2015

—

Drowsiness

—

Expected effect (intentional)

Vivid dreams

—

Anecdotally reported

Long-term safety

—

Limited modern RCT data

Pregnancy / OB

—

Avoid

Absolute Contraindications

ARA 290

·Hypersensitivity to ARA 290

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Relative Contraindications

ARA 290

·Active malignancy (theoretical EPO-axis concern; not observed in trials)

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

05Administration Protocol

Parameter

ARA 290

DSIP

1. Preparation

Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.

Add 1–2 mL bacteriostatic water to vial.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.

SQ — abdomen. Rotate sites.

3. Timing

Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015

30–60 min pre-sleep.

4. Dosing

4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Storage

Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.

29–31G insulin syringe.

06Stack Synergy

ARA 290

+ BPC-157

Moderate

View BPC-157 →

ARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.

ARA 290: 4 mg SQ · daily
BPC-157: 250–500 mcg SQ · daily
Frequency: Once daily, same or separate injections
Primary benefit: Nerve regeneration, pain reduction, tissue healing

DSIP

— no documented stacks